Paper Details

  1. Home
  2. Paper Details

Efficacy and safety of topical JAK inhibitors in the treatment of atopic dermatitis in paediatrics and adults: A systematic review.

Author: MohandesiNessa Aghazadeh, SadeghiSara

Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This systematic review examined the efficacy and safety of topical Janus Kinase inhibitors (JAKis) for the treatment of atopic dermatitis (AD). The review found that topical JAKis were effective in treating AD in adults and children, with minimal risk of mild-to-moderate adverse effects.
Paper Details　
Original Abstract of the Article :
Atopic dermatitis (AD) is the most common skin inflammatory disease. Dysregulation of innate and adaptive immune systems plays a major role in the pathophysiology of AD. JAKi (Janus Kinase Inhibitors) reduce the production of pro-inflammatory cytokines and represent a promising novel treatment for A...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/exd.14753

データ提供：米国国立医学図書館（NLM）

A New Era of Treatment: Topical JAK Inhibitors Offer Hope for Atopic Dermatitis

Atopic dermatitis, a chronic skin condition that causes itchy and inflamed skin, is a common challenge in the field of [dermatology]. This study explores the efficacy and safety of topical JAK inhibitors, a new class of medications, for treating atopic dermatitis in both adults and children. The research offers a potential breakthrough in managing this debilitating skin condition.

A New Path: Topical JAK Inhibitors Offer a Promising Solution

The study reveals that topical JAK inhibitors, such as delgocitinib, tofacitinib, and ruxolitinib, are effective in reducing symptoms of atopic dermatitis. This finding suggests that topical JAK inhibitors could provide a new and potentially more effective treatment option for patients struggling with this condition. It's like finding a new oasis in the desert of atopic dermatitis.

A Brighter Future: Hope for Atopic Dermatitis Patients

The research highlights the potential of topical JAK inhibitors to significantly improve the lives of patients with atopic dermatitis. The study's findings encourage further research to explore the long-term efficacy and safety of these medications.

Dr.Camel's Conclusion

This study is a beacon of hope for those navigating the desert of atopic dermatitis. Topical JAK inhibitors offer a promising new approach to managing this chronic condition, potentially leading to improved symptom control and a better quality of life for patients.

Date :
  1. Date Completed 2023-05-03
  2. Date Revised 2023-05-03
Further Info :

Pubmed ID

36691705

DOI: Digital Object Identifier

10.1111/exd.14753

Related Literature

Article Analysis
・Effects of ruxolitinib topical
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.